Literature DB >> 2546688

Severe renal toxicity due to intermediate-dose methotrexate.

A N Stark1, G Jackson, P J Carey, S Arfeen, S J Proctor.   

Abstract

Methotrexate (MTX) is a drug widely used in the treatment of patients with malignant disease. Its well-known side effects include myelosuppression, mucositis and renal damage. These problems are primarily dose-related, tending to occur more frequently when high doses (greater than 1 g/m2) are given. We present four cases in whom severe renal and mucosal toxicity occurred with intermediate doses (200 mg/m2) of MTX despite folinic acid rescue. Possible reasons for this occurrence are discussed and means of avoiding such toxicity are suggested. Three of four patients developed severe loin pain within a few hours of injection; the significance of this symptom in relation to subsequent renal toxicity has implications for early recognition of the problem.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546688     DOI: 10.1007/BF00257626

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Near fatal drug interactions with methotrexate given for psoriasis.

Authors:  H W Ng; A W Macfarlane; R M Graham; J L Verbov
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-26

Review 2.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

4.  Fatal interaction between methotrexate and naproxen.

Authors:  R R Singh; A N Malaviya; J N Pandey; J S Guleria
Journal:  Lancet       Date:  1986-06-14       Impact factor: 79.321

5.  Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen.

Authors:  A Thyss; G Milano; J Kubar; M Namer; M Schneider
Journal:  Lancet       Date:  1986-02-01       Impact factor: 79.321

6.  Influence of various beverages on urine acid output.

Authors:  E G de Vries; C Meyer; M Strubbe; N H Mulder
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

7.  Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy.

Authors:  C D Pusey; D Saltissi; L Bloodworth; D J Rainford; J L Christie
Journal:  Q J Med       Date:  1983

8.  7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

Authors:  S A Jacobs; R G Stoller; B A Chabner; D G Johns
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

9.  Methotrexate toxicity precipitated by azapropazone.

Authors:  H M Daly; G L Scott; J Boyle; C J Roberts
Journal:  Br J Dermatol       Date:  1986-06       Impact factor: 9.302

  9 in total
  8 in total

1.  Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate.

Authors:  J Shamash; H Earl; R Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.

Authors:  Erin Dombrowsky; Bhuvana Jayaraman; Mahesh Narayan; Jeffrey S Barrett
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681

3.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

4.  Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.

Authors:  Piali Mandal; Sukla Samaddar; Jagdish Chandra; Nupur Parakh; Manish Goel
Journal:  Indian J Hematol Blood Transfus       Date:  2020-01-02       Impact factor: 0.900

5.  Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis.

Authors:  P Seideman; R Müller-Suur
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

6.  Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats.

Authors:  Ihab T Abdel-Raheem; Naglaa F Khedr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-22       Impact factor: 3.000

7.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

8.  Proteinuria due to suboptimal hydration with high-dose methotrexate therapy.

Authors:  G T Kovács; C Paál; P Somló; R Koós; D Schuler; J D Borsi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.